List view / Grid view
7 January 2016 | By Nicholas Jackson
Plans for the world’s first clinical trial for a vaccine targeting Alzheimer’s disease-like characteristics in those with Down's syndrome have been announced...
4 January 2016 | By Victoria White
BPN14770 may be a possible treatment for dementia and Alzheimer’s disease with less potential for side effects than rolipram...
22 December 2015 | By Victoria White
A study suggests that enhancing proteasome activity with drugs during the early stages of Alzheimer’s may prevent dementia and reduce damage to the brain...
22 December 2015 | By Victoria White
The IMI has launched two Calls for proposals that will advance drug development in Ebola, childhood cancers, neurological disorders, and eye disease...
14 December 2015 | By Victoria White
A new study outlines a way of using antibiotic resistance to find chemicals capable of stopping amyloid formation in amyloid diseases such as Parkinson’s, Alzheimer’s and type II diabetes...
27 November 2015 | By Victoria White
Researchers have discovered how connections between brain cells are destroyed in the early stages of Alzheimer’s disease...
19 November 2015 | By Victoria White
Scientists have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue...
16 November 2015 | By Victoria White
Scientists have conducted research to suppress an abnormal assembly of beta-amyloids by using photo-excited porphyrins...
13 November 2015 | By Victoria White
Mice treated with J147 had better memory and cognition, healthier blood vessels in the brain and other improved physiological features...
6 November 2015 | By Victoria White
Scientists have discovered that small changes in anti-amyloid antibodies preserves the immunotherapeutic activity without the inflammatory side effects...
5 November 2015 | By Victoria White
The investigations were triggered when scientists observed that amyloid plaques were being cleared in mice with chronic brain inflammation...
21 October 2015 | By Kate Douetil
This innovative new global investment fund has gained support from a wide variety of investors, including the UK Government’s Department of Health (DoH), Alzheimer’s Research UK and world-leading major pharmaceutical companies Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda...
19 October 2015 | By Victoria White
Pyroglutamate-3 Abeta (pGlu-3 Abeta), a post-translational modified Abeta, is a highly toxic Abeta variant which is abundant in brains of patients with Alzheimer’s disease...
15 October 2015 | By Victoria White
Researchers have determined that the protein GPR3 might play an important role in alleviating the cognitive deficits of 'amyloid plaques'...
12 October 2015 | By Victoria White
The Dementia Consortium is a £3.5m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology, Eisai, Lilly and now Astex...
